Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 18Sarcoma 1Gynecologic 1

Conditions

Ovarian Neoplasms 3168Uterine Cervical Neoplasms 2191Endometrial Neoplasms 1334Breast Neoplasms 819Fallopian Tube Neoplasms 808Carcinoma, Ovarian Epithelial 772Neoplasms 540Colorectal Neoplasms 439Carcinoma, Non-Small-Cell Lung 420Uterine Cervical Dysplasia 376Pancreatic Neoplasms 363Stomach Neoplasms 354Prostatic Neoplasms 318Lung Neoplasms 315Melanoma 289Uterine Neoplasms 239Peritoneal Neoplasms 238Neoplasm Metastasis 238Vulvar Neoplasms 229Urinary Bladder Neoplasms 225Esophageal Neoplasms 225Head and Neck Neoplasms 222Sarcoma 219Carcinoma, Renal Cell 214Recurrence 213Colonic Neoplasms 210Papillomavirus Infections 206Triple Negative Breast Neoplasms 191Squamous Cell Carcinoma of Head and Neck 177Vaginal Neoplasms 147

Interventions

selurampanel 1Postmortem Imaging 1Magnetic Resonance Spectroscopy 1High-Energy Shock Waves 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adrenocortical Adenoma × Gynecologic × Clear all
NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Novartis

Phase 2 Completed
59 enrolled 6 charts
EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡